<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Open Forum Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">Open Forum Infect Dis</journal-id><journal-id journal-id-type="publisher-id">ofid</journal-id><journal-title-group><journal-title>Open Forum Infectious Diseases</journal-title></journal-title-group><issn pub-type="epub">2328-8957</issn><publisher><publisher-name>Oxford University Press</publisher-name><publisher-loc>US</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">5632232</article-id><article-id pub-id-type="doi">10.1093/ofid/ofx162.072</article-id><article-id pub-id-type="publisher-id">ofx162.072</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstracts</subject><subj-group subj-group-type="category-toc-heading"><subject>Oral Abstract</subject></subj-group></subj-group></article-categories><title-group><article-title>Doing the Same with Less: A&#x000a0;Randomized, Multinational, Open-Label, Adjudicator-Blinded Trial of an Algorithm vs. Standard of Care to Determine Treatment Duration for Staphylococcal Bacteremia</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Holland</surname><given-names>Thomas L</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Boucher</surname><given-names>Helen W</given-names></name><degrees>MD, FIDSA</degrees><xref ref-type="aff" rid="AF0002">2</xref></contrib><contrib contrib-type="author"><name><surname>Raad</surname><given-names>Issam</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0003">3</xref></contrib><contrib contrib-type="author"><name><surname>Anderson</surname><given-names>Deverick J</given-names></name><degrees>MD, MPH</degrees><xref ref-type="aff" rid="AF0004">4</xref></contrib><contrib contrib-type="author"><name><surname>Cosgrove</surname><given-names>Sara E</given-names></name><degrees>MD, MS</degrees><xref ref-type="aff" rid="AF0005">5</xref></contrib><contrib contrib-type="author"><name><surname>Aycock</surname><given-names>Suzanne</given-names></name><degrees>MSN</degrees><xref ref-type="aff" rid="AF0006">6</xref></contrib><contrib contrib-type="author"><name><surname>Baddley</surname><given-names>John W</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0007">7</xref></contrib><contrib contrib-type="author"><name><surname>Chow</surname><given-names>Shein-Chung</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Chu</surname><given-names>Vivian H</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Cook</surname><given-names>Paul P</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0008">8</xref></contrib><contrib contrib-type="author"><name><surname>Corey</surname><given-names>G Ralph</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Daly</surname><given-names>Jennifer S</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0009">9</xref></contrib><contrib contrib-type="author"><name><surname>Hachem</surname><given-names>Ray Y</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0010">10</xref></contrib><contrib contrib-type="author"><name><surname>Chaftari</surname><given-names>Anne-Marie</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0010">10</xref></contrib><contrib contrib-type="author"><name><surname>Horton</surname><given-names>James M</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0011">11</xref></contrib><contrib contrib-type="author"><name><surname>Jenkins</surname><given-names>Timothy C</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0012">12</xref></contrib><contrib contrib-type="author"><name><surname>Gu</surname><given-names>Jiezhun</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="AF0006">6</xref></contrib><contrib contrib-type="author"><name><surname>Levine</surname><given-names>Donald P</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0013">13</xref></contrib><contrib contrib-type="author"><name><surname>Miro</surname><given-names>Jose M</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="AF0014">14</xref><xref ref-type="aff" rid="AF0015">15</xref></contrib><contrib contrib-type="author"><name><surname>Riska</surname><given-names>Paul</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0016">16</xref></contrib><contrib contrib-type="author"><name><surname>Rubin</surname><given-names>Zachary A</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0017">17</xref></contrib><contrib contrib-type="author"><name><surname>Rupp</surname><given-names>Mark E</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0018">18</xref></contrib><contrib contrib-type="author"><name><surname>Schrank</surname><given-names>John</given-names><suffix>Jr.</suffix></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0019">19</xref></contrib><contrib contrib-type="author"><name><surname>Sims</surname><given-names>Matthew</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="AF0020">20</xref></contrib><contrib contrib-type="author"><name><surname>Wray</surname><given-names>Dannah</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0021">21</xref></contrib><contrib contrib-type="author"><name><surname>Zervos</surname><given-names>Marcus J</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0022">22</xref></contrib><contrib contrib-type="author"><name><surname>Fowler</surname><given-names>Vance</given-names><suffix>Jr.</suffix></name><degrees>MD, MHS</degrees><xref ref-type="aff" rid="AF0001">1</xref></contrib></contrib-group><aff id="AF0001">
<label>1</label>
<institution>Duke University Medical Center</institution>, <addr-line>Durham, North Carolina</addr-line>;</aff><aff id="AF0002">
<label>2</label>
<institution>Tufts Medical Center</institution>, <addr-line>Boston, Massachusetts</addr-line>;</aff><aff id="AF0003">
<label>3</label>
<institution>Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas M.D. Anderson Cancer Center</institution>, <addr-line>Houston, Texas</addr-line>;</aff><aff id="AF0004">
<label>4</label>
<institution>Division of Infectious Diseases, Duke University Medical Center</institution>, <addr-line>Durham, North Carolina</addr-line>;</aff><aff id="AF0005">
<label>5</label>
<institution>Johns Hopkins Medical Institutions</institution>, <addr-line>Baltimore, Maryland</addr-line>;</aff><aff id="AF0006">
<label>6</label>
<institution>Duke Clinical Research Institute</institution>, <addr-line>Durham, North Carolina</addr-line>;</aff><aff id="AF0007">
<label>7</label>
<institution>University of Alabama at Birmingham</institution>, <addr-line>Birmingham, Alabama</addr-line>;</aff><aff id="AF0008">
<label>8</label>
<institution>Infectious Diseases, Brody School of Medicine at East Carolina University</institution>, <addr-line>Greenville, North Carolina</addr-line>;</aff><aff id="AF0009">
<label>9</label>
<institution>University of Massachusetts Medical School</institution>, <addr-line>Worcester, Massachusetts</addr-line>;</aff><aff id="AF0010">
<label>10</label>
<institution>University of Texas MD Anderson Cancer Center</institution>, <addr-line>Houston, Texas</addr-line>;</aff><aff id="AF0011">
<label>11</label>
<institution>Carolinas Medical Center</institution>, <addr-line>Charlotte, North Carolina</addr-line>;</aff><aff id="AF0012">
<label>12</label>
<institution>Denver Health</institution>, <addr-line>Denver, Colorado</addr-line>;</aff><aff id="AF0013">
<label>13</label>
<institution>Wayne State University</institution>, <addr-line>Detroit, Michigan</addr-line>;</aff><aff id="AF0014">
<label>14</label>
<institution>Hospital Clinic-IDIBAPS</institution>, <addr-line>Barcelona</addr-line>, <country>Spain</country>;</aff><aff id="AF0015">
<label>15</label>
<institution>Hospital Cl&#x000ed;nic-IDIBAPS. University of Barcelona</institution>, <addr-line>Barcelona</addr-line>, <country>Spain</country>;</aff><aff id="AF0016">
<label>16</label>
<institution>Albert Einstein College of Medicine</institution>, <addr-line>Bronx, New York</addr-line>;</aff><aff id="AF0017">
<label>17</label>
<institution>David Geffen School of Medicine/University of California</institution>, <addr-line>Los Angeles</addr-line>, <addr-line>Los Angeles, California</addr-line>;</aff><aff id="AF0018">
<label>18</label>
<institution>Internal Medicine, Division of Infectious Diseases, University of Nebraska Medical Center</institution>, <addr-line>Omaha</addr-line>, <country>Nebraska</country>;</aff><aff id="AF0019">
<label>19</label>
<institution>Greenville Health System</institution>, <addr-line>Greenville, South Carolina</addr-line>;</aff><aff id="AF0020">
<label>20</label>
<institution>Beaumont Health System</institution>, <addr-line>Royal Oak, Michigan</addr-line>;</aff><aff id="AF0021">
<label>21</label>
<institution>Medical University of South Carolina</institution>, <addr-line>Charleston, South Carolina</addr-line>;</aff><aff id="AF0022">
<label>22</label>
<institution>Henry Ford Health System</institution>, <addr-line>Detroit, Michigan</addr-line></aff><author-notes><fn id="fn-0001"><p>
<bold>Session:</bold> 132. Advances in Management of Bacteremia and&#x000a0;Sepsis</p><p>
<italic>Friday, October 6, 2017: 10:30 AM</italic>
</p></fn></author-notes><pub-date pub-type="collection"><season>Fall</season><year>2017</year></pub-date><pub-date pub-type="epub" iso-8601-date="2017-10-04"><day>04</day><month>10</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>04</day><month>10</month><year>2017</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>4</volume><issue>Suppl 1</issue><issue-title>ID Week 2017 Abstracts</issue-title><fpage>S29</fpage><lpage>S29</lpage><permissions><copyright-statement>&#x000a9; The Author 2017. Published by Oxford University Press on behalf of Infectious Diseases Society of America.</copyright-statement><copyright-year>2017</copyright-year><license license-type="cc-by-nc-nd" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com</license-p></license></permissions><self-uri xlink:href="ofx162.072.pdf"/><abstract><title>Abstract</title><sec id="s1"><title>Background</title><p>The appropriate duration of antibiotics for staphylococcal bloodstream infection (BSI) is unknown. An algorithm to identify patients with staphylococcal BSI who can be safely treated with shorter courses of therapy would improve care and reduce total antibiotic&#x000a0;use.</p></sec><sec id="s2"><title>Methods</title><p>Adult patients with staphylococcal BSI were randomized to treatment based on algorithm-based therapy (ABT) or to standard of care (SOC). Co-primary outcomes were clinical success, as determined by a blinded Adjudication Committee, and serious adverse event (SAE) rates. The prespecified secondary outcome measure was antibiotic days by treatment group, among patients without complicated BSI. Prespecified durations of therapy in ABT were: <italic>S.&#x000a0;aureus</italic> BSI (SAB): uncomplicated: 14&#x000a0;days; complicated: 4&#x02013;6 weeks. Coagulase-negative staphylococci BSI (CoNSB): simple (1 positive blood culture) (0&#x02013;3&#x000a0;days), uncomplicated (&#x0003e;1 positive blood culture) (5&#x000a0;days), complicated (7&#x02013;28&#x000a0;days). Outcomes were compared using intention-to-treat principles. The target sample size was 500 patients, to ensure 90% power for establishing noninferiority within a margin of&#x000a0;15%.</p></sec><sec id="s3"><title>Results</title><p>Between April 2011 and March 2017, 509 adults with suspected staphylococcal BSI at 16 sites in the US and Spain were randomized to ABT (<italic>N</italic>&#x000a0;=&#x000a0;255) or SOC (<italic>N</italic>&#x000a0;=&#x000a0;254). There were 116 patients with SAB (23%) and 385 (76%) with CoNSB (Figure&#x000a0;1). Overall success rate in the ABT group was 82.0% vs. 81.5% in the SOC group, difference 0.5%, 95% CI &#x02212;5.2% to 6.1%. SAEs were reported in 32.9% of ABT vs. 28.3% of SOC patients (OR 1.2, 95% CI 0.9 to 1.8). Among evaluable patients without complicated BSI, mean duration of therapy was 4.4&#x000a0;days in the ABT group vs. 6.4&#x000a0;days in the SOC group (difference &#x02212;2.0&#x000a0;days, 95% CI &#x02212;3.3 to &#x02212;-0.7, <italic>P</italic>&#x000a0;=&#x000a0;0.003). Among patients with uncomplicated SAB, treatment durations were similar (15.3&#x000a0;days in ABT vs. 16.3&#x000a0;days in SOC, difference &#x02212;1&#x000a0;day, 95% CI &#x02212;3.89 to 1.91, <italic>P</italic>&#x000a0;=&#x000a0;0.497), whereas for uncomplicated CoNSB, duration was shorter in the ABT group (5.3&#x000a0;days in ABT vs. 8.4&#x000a0;days in SOC, difference &#x02212;3&#x000a0;days, 95% CI &#x02212;4.87 to &#x02212;1.34, <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001).</p></sec><sec id="s4"><title>Conclusion</title><p>The use of a treatment algorithm for staphylococcal BSI was associated with significant reductions in duration of antibiotic therapy in patients without complicated BSI, without significant differences in overall success or SAEs.</p><fig fig-type="figure" id="F1" orientation="portrait" position="float"><label>Figure&#x000a0;1.</label><caption><p>Schematic of Study&#x000a0;Design</p></caption><graphic xlink:href="OFIDIS_ofx162_IF0050"/></fig></sec><sec id="s5"><title>Disclosures</title><p>
<bold>V.&#x000a0;Fowler Jr.</bold>, NIH: Investigator, Contract HHSN272200900023C</p></sec></abstract><counts><page-count count="1"/></counts></article-meta></front></article>